Geode Capital Management
APRE icon

Geode Capital Management’s Aprea Therapeutics APRE Stock Holding History

Geode Capital Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.1K Sell
74,869
-44,262
-37% -$36.9K ﹤0.01% 4204
2026
Q1 		$90.9K Buy
119,131
+78,181
+191% +$61.5K ﹤0.01% 4160
2025
Q4 		$34.9K Sell
40,950
-3,666
-8% -$4.5K ﹤0.01% 4295
2025
Q3 		$65.8K Buy
44,616
+1,479
+3% +$2.43K ﹤0.01% 4233
2025
Q2 		$73.3K Hold
43,137
– – ﹤0.01% 4142
2025
Q1 		$88K Buy
43,137
+474
+1% +$1.49K ﹤0.01% 4069
2024
Q4 		$140K Buy
42,663
+2,596
+6% +$8.68K ﹤0.01% 4001
2024
Q3 		$110K Buy
40,067
+4,394
+12% +$15.5K ﹤0.01% 4080
2024
Q2 		$145K Buy
35,673
+15,452
+76% +$79.7K ﹤0.01% 4022
2024
Q1 		$135K Buy
20,221
+2,748
+16% +$17.1K ﹤0.01% 4061
2023
Q4 		$82.2K Hold
17,473
– – ﹤0.01% 4241
2023
Q3 		$73.2K Sell
17,473
-6,117
-26% -$22.3K ﹤0.01% 4326
2023
Q2 		$74.3K Buy
+23,590
New +$87.9K ﹤0.01% 4421
2023
Q1 		– Sell
-7,486
Closed -$48K – 4806
2022
Q4 		$48K Sell
7,486
-21
-0.3% -$222 ﹤0.01% 4599
2022
Q3 		$97K Hold
7,507
– – ﹤0.01% 4587
2022
Q2 		$111K Hold
7,507
– – ﹤0.01% 4548
2022
Q1 		$279K Hold
7,507
– – ﹤0.01% 4212
2021
Q4 		$430K Sell
7,507
-2,410
-24% -$213K ﹤0.01% 4128
2021
Q3 		$1.01M Buy
9,917
+4,695
+90% +$426K ﹤0.01% 3666
2021
Q2 		$509K Sell
5,222
-2,835
-35% -$262K ﹤0.01% 3935
2021
Q1 		$821K Buy
8,057
+672
+9% +$78.4K ﹤0.01% 3641
2020
Q4 		$726K Buy
7,385
+718
+11% +$341K ﹤0.01% 3468
2020
Q3 		$3.21M Buy
6,667
+1,359
+26% +$761K ﹤0.01% 2634
2020
Q2 		$4.12M Buy
5,308
+502
+10% +$329K ﹤0.01% 2448
2020
Q1 		$3.34M Buy
4,806
+439
+10% +$322K ﹤0.01% 2376
2019
Q4 		$4.01M Buy
+4,367
New +$2.4M ﹤0.01% 2592

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Geode Capital Management's APRE Position: Q2 2026 in Review

Geode Capital Management reduced its Aprea Therapeutics (APRE) stake by 37% in Q2 2026, selling an estimated $36.9K and leaving 74,869 shares worth $60.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4204.

Geode Capital Management first reported a position in APRE in Q4 2019 and has held it in 26 quarters since. The position peaked at $4.12M in Q2 2020. 18 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • Geode Capital Management held 74,869 shares of Aprea Therapeutics worth $60.1K as of Q2 2026.
  • Geode Capital Management sold 44,262 Aprea Therapeutics shares in Q2 2026, an estimated $36.9K.
  • Aprea Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4204 holding.
  • Geode Capital Management first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • Geode Capital Management's Aprea Therapeutics position peaked at $4.12M in Q2 2020.
  • 18 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.